We are live on ! Find out more

Harvard Bioscience

HBIO

Market cap $37.6M

8.25 USD

-0.09

1.08%

At close Updated Oct 21, 12:12 PM EDT

1 day

-1.08%

5 days

0.49%

1 month

3.13%

3 months

36.59%

6 months

25.76%

Year to date

26.53%

1 year

101.22%

5 years

-88.33%

10 years

-68.87%

About: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Employees: 339

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Harvard Bioscience Announces Creation of Scientific Advisory Board

HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company's ongoing research, development, and new product roadmaps.

Harvard Bioscience Announces Creation of Scientific Advisory Board

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET

HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026, and will hold a conference call to discuss the results at 8:00 a.m.

Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience Announces First Quarter 2026 Financial Results

First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.

Harvard Bioscience Announces First Quarter 2026 Financial Results

Harvard Bioscience to Participate in Upcoming Investor Conferences

HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events.

Harvard Bioscience to Participate in Upcoming Investor Conferences

Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET

HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m.

Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the fourth quarter and full year ended December 31, 2025.

Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results

Harvard Bioscience Announces Reverse Stock Split

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company's 1-for-10 reverse stock split (the “Reverse Split”) of the Company's common stock, par value $0.01 per share.

Harvard Bioscience Announces Reverse Stock Split

See News Rankings

Price charts implemented using Lightweight Charts™